Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges

Bagno, Luiza; Hatzistergos, Konstantinos E.; Balkan, Wayne; Hare, Joshua M.

doi:10.1016/j.ymthe.2018.05.009

Cited by 249 publications

(177 citation statements)

References 182 publications

(276 reference statements)

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Those drugs are slowly released from the exosomes and result in higher drug accumulation in target cells and longer blood circulation time and enhanced therapeutic efficacy 107 . MSC‐derived exosomes have been engineered as an efficient delivery system reported to exert higher anti–tumor efficacy and reduced toxicity 108,109 . For instance, BMSC‐derived exosomes encapsulated with doxorubicin are preferentially taken up by human epidermal growth factor receptor 2+ (HER2+) cells in vitro, leading to an inhibitory effect in a breast tumor model 110 .…”

Section: Introductionmentioning

confidence: 99%

“…Currently, there are nine studies undergoing clinical trials, and they are listed in www.clinicaltrials.govhttp://. 109 A combination of ascites‐derived exosomes with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) underwent a phase I clinical trial for the treatment of advanced colorectal cancer, which was shown to be feasible and safe and also capable of triggering more CTL infiltration in tumor regions 112 . Another phase I clinical trial using exosome delivery of curcumin to colon tumors and normal colon tissue was started in 2011 and is estimated to end in 2020 (ClinicalTrials.gov identifier: NCT01294072).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biology and therapeutic potential of mesenchymal stem cell‐derived exosomes

2020

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) are multipotent stromal cells with the potential to differentiate into several cell types. MSC‐based therapy has emerged as a promising strategy for various diseases. Accumulating evidence suggests that the paracrine effects of MSC are partially exerted by the secretion of soluble factors, in particular exosomes. MSC‐derived exosomes are involved in intercellular communication through transfer of proteins, RNA, DNA and bioactive lipids, which might constitute a novel intercellular communication mode. This review illustrates the current knowledge on the composition and biological functions as well as the therapeutic potential of MSC‐derived exosomes in cancer, with a focus on clinical translation opportunities.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biology and therapeutic potential of mesenchymal stem cell‐derived exosomes

2020

View full text Add to dashboard Cite

show abstract

“…To date, current clinical regimens largely rely on the administration of drugs and other therapeutic agents such as the stem cell and the growth factors (Madonna and De Caterina, 2011;Bagno et al, 2018), basing on the hypothesis that a certain disease consists of dysfunctional cells and molecules within healthy organs and body. As well known, on the one hand, drugs or other therapeutic materials need to overcome physiological barriers to reach targets sites and during the process of transporting them, potential adverse effects may be produced; on the other hand, another hamper is the retention time of agents in the injury site is not adequate for new vessel growth.…”

Section: Introductionmentioning

confidence: 99%

Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases

Liao

Yang

Deng

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs), including a series of pathological disorders, severely affect millions of people all over the world. To address this issue, several potential therapies have been developed for treating CVDs, including injectable hydrogels as a minimally invasive method. However, the utilization of injectable hydrogel is a bit restricted recently owing to some limitations, such as transporting the therapeutic agent more accurately to the target site and prolonging their retention locally. This review focuses on the advances in injectable hydrogels for CVD, detailing the types of injectable hydrogels (natural or synthetic), especially that complexed with stem cells, cytokines, nano-chemical particles, exosomes, genetic material including DNA or RNA, etc. Moreover, we summarized the mainly prominent mechanism, based on which injectable hydrogel present excellent treating effect of cardiovascular repair. All in all, it is hopefully that injectable hydrogel-based nanocomposites would be a potential candidate through cardiac repair in CVDs treatment.

show abstract

“…Mesenchymal stem cells (MSCs) therapy is widely used in the area of cardiovascular regeneration [1].…”

Section: Introductionmentioning

confidence: 99%

Hypoxia preconditioning promotes mesenchymal stem cells survival and vascularization through the activation of MALAT1/miR-195/VEGFA axis

Hou

Wang

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies have demonstrated that hypoxia preconditioning (HP) can promote mesenchymal stem cells (MSCs) survival and vascularization. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a newly discovered regulator of MSCs viability and differentiation. Evidences have indicated that MALAT1 can be strongly induced by hypoxia. This study aimed to investigate the role of MALAT1 in HP mediated MSCs survival and vascularization as well as the relevant underlying mechanism in vitro.Methods: MSCs were obtained from C57BL/6 mice and cultured in vitro. Cells at the third passage were divided into the following groups: normoxia (N), hypoxia preconditioning (HP), HP + MALAT1, HP + MALAT1 NC, HP+si-MALAT1 and HP +si-MALAT1 NC. The normoxia group was cultured in 20% O2 for 24 h. All the other groups were exposed to hypoxia (1% O2) for 24 hours. MALAT1 and relevant scramble RNA were transfected in the HP+MALAT1 and HP+MALAT1 NC groups respectively. HP+si-MALAT1 and HP +si-MALAT1 NC groups were transfected with MALAT1 siRNA and relevant siRNA scramble respectively. MSCs proliferation, apoptosis and vascular densities were evaluated. Bioinformatics and dual luciferase reporter assay were performed. Relevant biomarkers were examined in different experimental groups.Results: MSCs survival and vascularization were significantly enhanced in the HP group. Transfection of MALAT1 further strengthened the viability and angiogenic potential of MSCs in the condition of HP, whereas its knockdown attenuated cells survival and vascularization. MALAT1 and vascular endothelial growth factor A (VEGFA) were obviously increased after hypoxia exposure, while miR-195 was decreased. miR-195 targeted and downregulated VEGFA. miR-195 was a target of MALAT1. Overexpression of MALAT1 led to a decreased level of miR-195, accompanied with an augmented expression of VEGFA. However, both miR-195 and VEGFA exhibited contrary alterations after MALAT1 blockage. Conclusion: HP enhanced MSCs survival and vascularization potential in vitro, and the activation of MALAT1/miR-195/VEGFA axis might be involved in this procedure. This study reveals a new molecular mechanism of HP mediated MSCs survival and vascularization. It will be conducive for the development of novel strategies to improve the therapeutic efficiency of MSCs based on HP.

show abstract

Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges

Cited by 249 publications

References 182 publications

Biology and therapeutic potential of mesenchymal stem cell‐derived exosomes

Biology and therapeutic potential of mesenchymal stem cell‐derived exosomes

Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases

Hypoxia preconditioning promotes mesenchymal stem cells survival and vascularization through the activation of MALAT1/miR-195/VEGFA axis

Contact Info

Product

Resources

About